Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time. Similarly, biotech stocks can ...
Summary Heron addressed a key problem recently - its cash balance and cash burn. The cash raised and cost reductions have significantly extended the cash runway. However, much better growth of Zynrelef is required for the stock to recover in a more meaningful way. Aponvie'...
Commercial-stage biotech Heron Therapeutics, Inc. ( NASDAQ: HRTX ) announced Friday that the FDA approved its intravenous injection Aponvie (aprepitant) for the prevention of postoperative nausea and vomiting (PONV) in adults. HRTX shares are currently on hold for trading. ...
Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) PR Newswire - APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK 1 ) receptor antagoni...
Good news from the Food and Drug Administration (FDA) can send biotech stocks into the stratosphere. And bad news can bring their share prices crashing down. Our Foolish trio is optimistic about Mirati Therapeutics (NASDAQ: MRTX) , Novavax (NASDAQ: NVAX) and Heron Therapeu...
Since the mid-June lows, highly shorted names have again been outperforming. On a relative basis, the most heavily shorted stocks have been outperforming the Russell 3,000 in that time. This has resulted in the relative strength line to break out of the downtrend that has been in ...
Heron Therapeutics, Inc. (HRTX) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants David Szekeres – Executive Vice President, Chief Operating Officer Barry Quart – Chief Executive Officer and Chairman John Poyhonen ...
Heron Therapeutics ( NASDAQ: HRTX ) is trading 16% higher after it reported better-than-expected Q2 revenue, helped by higher sales of postoperative pain drug Zynrelef. The company also raised full-year net product sales guidance to $93M to $95M from prior guidance...
The following slide deck was published by Heron Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Heron Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Gainers: Verona Pharma VRNA +87% . Mersana Therapeutics ( MRSN ) +38% . GoodRx Holdings ( GDRX ) +19% . Atara Biotherapeutics ( ATRA ) +22% . Heron Therapeutics HRTX +16% . Losers: CorMedix ( CRMD ) -56% . Qu...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...